INTEREST in the use of chemotherapeutic agents for palliating the clinical effects of malignant neoplasms is increasing. Cancer chemotherapy is especially useful when recurrence or metastasis follows surgery, or radiotherapy, or both and when massive size or the presence of distant metastases at the time of discovery precludes the use of these conventional methods. Most childhood cancers have some degree of responsiveness to one or more of the various available chemical compounds.
Sarcomas of the soft tissues in children tend to be highly malignant and to have a rather discouraging outlook. Bowden's1 five-year survival rate for 602 patients with soft-part sarcomas was 37%. Other mortality figures are higher. Lawrence et al2 reported 9 of 48 patients with embryonal rhabdomyosarcoma surviving and Masson and Soule3 found that 88% of traced patients with embryonal rhabdomyosarcoma of the head and neck died within five years. A number of agents have
Haddy TB, Nora AH, Sutow WW, Vietti TJ. Cyclophosphamide Treatment for Metastatic Soft Tissue Sarcoma: Intermittent Large Doses in the Treatment of Children. Am J Dis Child. 1967;114(3):301–308. doi:10.1001/archpedi.1967.02090240115010
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: